The aim of the study was to alleviate graft-versus-host reaction (GVHR) by pre-treatment of the bone marrow (BM) transplant with hydrocortisone (HC) and cyclosporin A (CsA) in C57BL/6J (donor) → CBA/J (recipient) mouse combination. BM cells were exposed to HC and CsA for 1 h at 37؇C and then injected into lethally irradiated (9.5 Gy) mice at a dose of 2 × 10 6 BM cells/mouse. Haematopoietic recovery was assessed on day 12, and survival was followed for 100 days. Combinations of 1000 g/ml HC and 100 g/ml CsA, and 100 g/ml HC and 10 g/ml CsA significantly reduced MLR and additively mitigated GVHR in vivo, achieving 40% and 26% survival rates, respectively. However, HC and CsA altered neither the peripheral blood cell counts nor in vitro and in vivo BM cell clonogenic potential. Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8 + and CD4
Transplantation of autologous, allogeneic or syngeneic haematopoietic cells has been accepted as a routine method of treatment of various malignant and non-malignant diseases. 1, 2 Generally, the concept of its curative therapy is based on the fact that haematological rescue with stem cells allows the administration of supralethal doses of antitumour drugs and/or irradiation. 3, 4 Allogeneic haematopoietic cell transplantation suffers from a graft-versus-host reaction (GVHR) 5, 6 that is caused by mature T cells in the transplant, 7, 8 but these same cells are useful because they
Correspondence: Dr D Grcević, Department of Physiology, Zagreb University School of Medicine, Salata 3, 10000 Zagreb, Croatia Received 4 September 1998; accepted 4 January 1999 enhance engraftment and haematopoietic recovery of the recipient. 4 Consequently, it would be desirable to dissociate the GVHR effects of the transplanted mature T cells from enhancement of haematopoietic recovery. 7 That can be achieved if the T cells are not completely removed from the transplant but rather affected so as to retain the stimulatory effect on differentiation of haematopoietic stem cells, 9 while simultaneously losing GVHR triggering potential. 10 Along this line of reasoning, in our study we avoided depletion of T cells from the allogeneic transplant, but concentrated on mitigation of their expected GVHR effects. We hoped that not only would the GVHR effects of transplanted T cells be mitigated, but also their beneficial effects upon recipients' haematopoietic recovery would be spared. In essence, our approach included a pre-transplantation, ex vivo, simple and short-term exposure of the transplant bone marrow (BM) cells to two widely used immunosuppressive drugs. Accordingly, transplant T cells were pretreated for 1 h at 37°C with hydrocortisone (HC) and/or cyclosporin A (CsA). HC and CsA were chosen because HC adversely affects mostly inflammatory cells, [11] [12] [13] which adds to the GVHR, whereas CsA hinders the activation of T lymphocytes, [14] [15] [16] which are the main GVHR effector cells. The pre-treatment indeed abrogated T cell activation and alleviated the development of GVHR, sparing at the same time the haematopoietic stem cells. The results call for investigation of the pre-treatment's potential for clinical application, and a search for even more effective pharmacological BM transplant conditioning.
Materials and methods

Animals
Mouse strains C57BL/6J (H-2 b ) and CBA/J (H-2 k ) were bred and maintained in the Animal Colony of the Department of Physiology, Zagreb University School of Medicine, Croatia. The animals were fed ad lib with standard mouse chow (Pliva, Zagreb, Croatia) and given water ad lib. Female and male mice, aged 10-12 weeks, were used in all experiments.
Pharmacological pre-treatment
In all experiments ex vivo pre-treatment consisted of 1 h incubation of cells in concentration of 2 × 10 7 /ml at 37°C with various concentrations of CsA (Sandoz Pharmaceutical, Basel, Switzerland) and HC (Sanavita, Werne, Germany). After incubation the cells were washed twice and used for further experiments.
Bone marrow transplantation (BMT)
CBA/J recipient mice were lethally irradiated with 9.5 Gy (LD 100 -Co 60 source). At 1-6 h after total body irradiation (day 0), mice were given i.v. 2 × 10 6 BM cells (resuspended in 1 ml sterile PBS) obtained from the femurs and tibias of donor mice (CBA/J and C57BL/6J). The viability of the BM cells was assessed by trypan blue exclusion and it was always above 95%. All recipient mice were treated with gentamicin (Pliva) for 15 days (from 5 days before to 10 days after BMT) to reduce intestinal microflora. Radiation controls received no BM cells and died after 14-22 days following irradiation.
GVHR assessment
GVHR was diagnosed by checking the animals daily for signs of GVHR (hunched posture, wasting, skin lesions and diarrhea). Survival of the recipients was followed for 100 days post transplantation, and was plotted on Kaplan-Meier survival curves. All experimental groups had 12 animals.
Assessment of haematopoietic recovery
On day 12 post transplantation haematopoietic recovery of mice (six per group) was assessed by peripheral blood analyses, macroscopic spleen colony assay and bone marrow smears. Peripheral blood was collected in K 2 -EDTA coated Microtainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA) from the retroorbital plexus of anaesthetised mice and analysed (number of leucocytes, lymphocytes, erythrocytes and platelets) by an electronic counter (Cobas-Argos, Roche & ABX, Basel, Switzerland). Spleens were removed and placed in Bouin's fixative, and macroscopic colonies were counted as spleen colony-forming units (CFU-S) according to the surface nodule assay system of Till and McCulloch. 17 Bone marrow smears were prepared from a single femur marrow, stained with May-Grün-wald-Giemsa and analysed under the light microscope for the presence of granulocytic, erythroid and megakaryocytic lineages.
T cell proliferation assay
Cells were isolated from C57BL/6J mouse lymph nodes and BM, pretreated with HC and/or CsA, washed in phosphate-buffered saline (PBS), resuspended in RPMI 1640 (Croatian Institute for Immunology, Zagreb, Croatia), and stimulated with the T cell mitogen, concanavalin A (con A) (Sigma, St Louis, MO, USA). Cells were seeded in triplicate at 0.2 ml/well containing 5 g con A, 10 5 lymph node cells (LNC) or 5 × 10 4 BM cells, 10% fetal calf serum (FCS) (Sigma), and 5 × 10 −5 ␤-mercaptoethanol (Sigma) in 96-well flat-bottom plates (Costar, Cambridge, MA, USA) and cultured for 72 h at 37°C with 5% CO 2 in air. Proliferation was assessed by the colorimetric MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide; Sigma) assay. 18 Ratios of optical density (OD) of con A-stimulated and unstimulated cultures represented stimulation indices. Percent reduction of cell proliferation was calculated by relating the stimulation indices of the pre-treated cells with those in the cultures with non-pretreated cells. responder BM cells, 10% FCS, and 5 × 10 −5 ␤-mercaptoethanol in 0.2 ml/well were seeded in triplicate in 96-well round-bottom plates (Costar) and cultured for 4 days at 37°C with 5% CO 2 in air. The proliferation was assessed by the colorimetric MTT assay. 18 Individual allogeneic MLR values were obtained as a mean OD of triplicate samples, after the OD of wells stimulated with syngeneic spleen cells had been deducted. The results were expressed as percent reduction of proliferation in comparison to untreated allogeneic MLR control.
Mixed lymphocyte reaction (MLR)
Isolated
Colony-forming unit (CFU) assay
For in vitro haematopoietic colony formation assay, triplicate methylcellulose cultures were set up using 24-well flatbottom plates (Costar) and seeded with 0.5 ml of complete HCC-3434 culture medium (Terry Fox Laboratories, Vancouver, Canada) containing 5 × 10 4 BM cells. BM cells from C57BL/6J mice pretreated with HC and/or CsA were cultured for 10 days at 37°C with 5% CO 2 in air. At day 10, erythroid (BFU-E), granulocyte-macrophage (CFU-GM) and mixed (CFU-GEMM) colonies containing more than 40 cells were counted.
CD4 and CD8 antigen expression and cell cycle analysis
LNC from C57BL/6J mice were isolated, pretreated, and seeded in the same way as those for the proliferation assay. Cells were cultured at 37°C with 5% CO 2 in air, and harvested after 24, 48, and 72 h. Harvested cells were washed with 0.1% NaN 3 in PBS and analysed by flow cytometry (FC) using FACScan analyser (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).
For two-color FC analysis, LNC were stained with PEanti-CD4 and FITC-anti-CD8 antibodies (Sigma). Briefly, 10 6 LNC were incubated with anti-CD4 and anti-CD8 antibodies for 30 min at 4°C, then washed twice with PBS, and immediately analysed using Cell-Quest software (Becton Dickinson Immunocytometry Systems).
For cell cycle analyses, 10 6 LNC were resuspended in 100 l of PBS and then incubated with 0.5 mL of DNA staining solution (0.01 m Tris, 10 mm NaCl, 700 U RNAse, 7.5 × 10 −5 m propidium iodide, 0.01% Nonidet P-40; Sigma) for 30 min in dark. DNA content was analysed using Cell-Quest and Mod-Fit LT software (Verity Software House, Topsham, ME, USA).
Reverse transcription-polymerase chain reaction (RT-PCR) procedure
BM cells were seeded in six-well flat-bottom plates (Costar) in 4 ml at a concentration of 2 × 10 7 cells/well, stimulated with 5 g of con A and cultured for 32 h. Total RNA was extracted from the BM cells using a commercial kit (Tri-Reagent; Molecular Research Center, Cincinnati, OH, USA). RNA was converted into complementary DNA (cDNA) by reverse transcriptase (Superscript II; Gibco, Grand Island, NY, USA). An initial RT mixture of total RNA (10 g), random hexamer, and RNAse inhibitor was incubated at 70°C for 10 min and then quenched on ice before RT buffer (50 mmol/l Tris-HCl pH 8.3, 75 mmol/l KCl, 3 mmol/l MgCl 2 ), dNTPs, DTT, and reverse transcriptase were added. The final mixture was incubated for 1 h at 37°C, pulsed with reverse transcriptase, and incubated for another 1 h at 37°C. The first strand cDNA, with sonicated salmon sperm DNA as a carrier, was extracted with phenol/chloroform, precipitated with ethanol, resuspended in sterile water, and amplified by PCR with Taq polymerase (Amplitaq; Perkin Elmer, Norwalk, CT, USA). PCR was performed in a thermal cycler (Perkin Elmer, Branchburg, NJ, USA). The temperature cycling was as follows: denaturation for 1 min at 94°C, primer annealing for 2 min at 65°C, and extension for 3 min at 72°C for 10 cycles. In subsequent cycles, the primer annealing temperature was decreased stepwise down to 45°C by increments of 5°C every five cycles. After the last cycle (total 30 cycles), the mixture was incubated for 7 min at 72°C. Specific amplimer sets (interleukin 1 (IL-1), interleukin 2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor ␤ (TGF-␤) and ␤-actin antisense and sense) were created according to the literature, 19 and synthesised by Integrated DNA Technologies, Coralville, IA, USA. The RT-PCR products were separated electrophoretically on 2% agarose gel stained with ethidium bromide, and viewed under UV illumination. For each set of primers, negative controls of the PCR assay were made, as well as commercially available positive control for ␤-actin. Each PCR assay was repeated twice with the same cDNA source to ensure the reproducibility of the assay.
Statistics
Significant differences among the groups of in vitro assays were determined using ANOVA with Sheffe post-hoc test. The values were presented as means Ϯ standard deviation (s.d.). Results were expressed as P values, and P values less than 0.05 were considered significant. Significance of the differences in the survival curves were determined using log-rank nonparametric test. The P values less than 0.05 were considered significant, ie allowed us to proceed to group-to-group comparisons. The significant P value for group-to-group comparison was determined as 0.05/number of comparisons, which was 0.0083. cells/ml. The proliferation was assessed by MTT assay. All applied drug doses significantly (at P Ͻ 0.05 probability level) reduced cell proliferation in comparison to drug non-treated control.
Table 1
In vitro proliferation of C57BL/6J lymph node and bone marrow cells pre-treated with cyclosporin A and/or hydrocortisone after 4 day co-cultivation with CBA/J mitomycin-treated spleen cells 
Results
Pre-treatment with HC and/or CsA inhibits con A-driven T cell proliferation and mixed lymphocyte reaction
In the first series of experiments we tested the ability of various doses of HC and CsA and their combinations to inhibit T cell mitogen (con A)-stimulated proliferation of C57BL/6J BM cells or LNC. As shown in Figure 1 , both HC and CsA inhibited cell proliferation of BM cells in a dose-dependent manner. Their inhibition had an additive effect, which was seen better at smaller doses of both drugs ( Figure 1 ). Similar results were obtained with LNC (data not shown), where both drugs exerted a stronger inhibition of proliferation. For example, doses of 1000 g/2 × 10 7 cells/ml HC and 100 g/2 × 10 7 cells/ml CsA completely abrogated proliferation of LNC, whereas the same pre-treatment resulted in a 68.0 Ϯ 5.03% inhibition of the BM cell proliferation (Figure 1) . Again, the additive effect of the two drugs on cell proliferation was more pronounced for LNC (data not shown). According to the results of con Astimulated proliferation suppression, we chose 100 and 1000 g/2 × 10 7 cells/ml HC, and/or 10 and 100 g/2 × 10 7 cells/ml CsA as the pre-treatment doses for MLR ( Table 1) . The drugs exerted a strong antiproliferative effect which appeared even stronger than that in cultures stimulated with con A. For example, the doses of 1000 g/ml HC and 100 g/ml CsA resulted in a 89.8 Ϯ 7.1% reduction of BM cell proliferation in MLR (Table 1) in comparison to a 68.0 Ϯ 5.03% reduction of con A-driven BM cell proliferation ( Figure 1 ). An additive effect was seen at smaller doses, which proved statistically significant for LNC (31.7 Ϯ 11.9% reduction with 10 g/ml CsA alone, 26.3 Ϯ 4.6% reduction with 100 g/ml HC alone in comparison to 83.8 Ϯ 1.5% reduction with both drugs). On the basis of the MLR results we assumed that the same doses would have sufficient GVHR inhibition potential in vivo.
BM pre-treatment with HC and/or CsA does not affect clonogenic potential of BM progenitor cells
It is imperative that any treatment of the BM transplant does not adversely affect the function or diminish the number of haematopoietic progenitor cells. We tested the effect of pharmacological pre-treatment of C57BL/6J BM cells on their clonogenic potential in vitro prior to the experiments in vivo. After the pre-treatment of cells (2 × 10 7 /ml) with 100 or 1000 g/ml HC, and/or 10 or 100 g/ml CsA respectively, the cells were cultured and the number of BFU-E, CFU-GM and CFU-GEMM colonies were scored on day 10 ( Table 2) . Neither of the two drugs, alone or combined, diminished the number of colonies. CsA pre- /mouse of syngeneic (top) or allogeneic C57BL/6J (H-2 b ) (bottom) bone marrow cells (12 mice per group). The cells (2 × 10 7 /ml) were pretreated for 1 h at 37°C with 1000 g/ml hydrocortisone (HC) and/or 100 g/ml cyclosporin A (CsA). Significant differences: allogeneic combination: CsA vs control (C) (P = 0.007), and HC + CsA vs C (P = 0.003).
treatment actually significantly increased the number of erythroid colonies at both concentrations, which was reflected as a significant increase of the total number of colonies. It is interesting that HC at a higher (1000 g/ml) dose abolished this enhancing effect of CsA, although it did not diminish the number or composition of colonies by itself.
Pre-treatment of BM cells with HC and/or CsA alleviates GVHR in allogeneic donor-host combination
The LD 100 of irradiation and the dose of BM cells that protects all irradiated mice from radiation death were determined in preliminary experiments (data not shown). In the experiments testing in vivo pre-treatment of donor BM with HC and/or CsA, CBA/J mice were lethally (9.5 Gy) irradiated and reconstituted with 2 × 10 6 pre-treated BM cells from syngeneic (CBA/J) or allogeneic (C57BL/6J) donors. All experimental groups had 12 CBA/J recipients. Radiation controls received no BM cells and died after 14-22 days following irradiation.
In the first set of in vivo experiments, the pre-treatment dose was 2000 g/2 × 10 7 cells/ml HC and 200 g/2 × 10 7 cells/ml CsA (data not shown). This dose of HC proved to be too high, because all mice which received HC pretreated BM cells died, regardless of whether the BM donors were syngeneic or allogeneic. The chosen dose of CsA was also partially toxic and killed some 40% of recipients of syngeneic BM, but also showed an anti-GVHR effect, because significantly more recipients of allogeneic bone marrow survived when the BM cells were pre-treated with CsA (P = 0.003). These results prompted us to lower the doses of the drugs used for the pre-treatment.
In the second set of in vivo experiments we used doses of 1000 g/2x10 7 cells/ml HC and 100 g/2 × 10 7 cells/ml CsA. This CsA dose was not toxic but HC retained a degree of toxicity (Figure 2, top) . Regarding the extent of alleviation of GVHR in the allogeneic donor-host combination, CsA alone (P = 0.007) and in combination with HC (P = 0.003) enabled significantly more irradiated recipients to survive (Figure 2, bottom) , but HC was ineffective. The pre-treatment of the allogeneic BM with the two drugs resulted in the survival of more recipients, but the difference in the survival of the recipients given allogeneic bone marrow pre-treated with either of the drugs alone was not statistically significant (Figure 2 , bottom; P = 0.19 for HC alone and P = 0.09 for CsA alone in comparison to pretreatment with both drugs).
The third set of in vivo experiments was conducted to test the dose of HC which would not adversely affect the survival of recipients of syngeneic BM but would still significantly alleviate the GVHR. Thus, the dose of 100 g/2 × 10 7 cells/ml HC and 10 g/2 × 10 7 cells/ml CsA were chosen for the pre-treatment. As presented in Figure 4 , these doses were not toxic for BM cells (Figure 3 , top) but the anti-GVHR effect of CsA disappeared, whereas the pre-treatment of allogeneic BM cells with HC alone showed marginal anti-GVHR effectiveness (P = 0.008, in comparison to survival of recipients of non-pre-treated allogeneic BM cells). The combination of the two drugs was most effective in alleviating GVHR (P = 0.005, in comparison to the survival of recipients of non-pre-treated BM cells), showing an additive effect of this drug dose (Figure 3, bottom) . 7 /ml) were pretreated for 1 h at 37°C with 100 g/ml hydrocortisone (HC) and/or 10 g/ml cyclosporin A (CsA). Significant differences: allogeneic combination: HC vs control (C) (P = 0.008), and HC + CsA vs C (P = 0.005).
Haematopoietic recovery was not adversely affected by the pre-treatment of bone marrow transplant T cells with CsA and HC
Figure 4
Alteration of cytokine gene expression by HC and CsA pretreatment of C57BL/6J bone marrow cells stimulated in vitro for 32 h with con A. RT-PCR products were made using amplimer sets for interleukin 1 (IL-1), interleukin 2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor ␤ (TGF-␤) and ␤-actin, and electrophoretically separated. Bone marrow cells (2 × 10 7 /ml) were treated for 1 h at 37°C with hydrocortisone (HC) and/or cyclosporin A (CsA). Drug concentrations are given in g/2 × 10 7 cells/ml. ␤-actin served as control house-keeping ubiquitous gene. The data are from a representative of two independent experiments with consistent results. geneic or allogeneic bone marrow cells pre-treated with 100 or 1000 g/2 × 10 7 cells/ml HC and 10 or 100 g/2 × 10 7 cells/ml CsA, respectively ( Table 3 ). The drugs did not adversely affect haematological recovery (white blood cells, lymphocytes, platelets and macroscopic spleen colony Recipient mice (CBA/J) were irradiated with 9.5 Gy and reconstituted with 2 × 10 6 bone marrow cells. Transplant T cells were pre-treated with cyclosporin A and/or hydrocortisone for 1 h at 37°C (doses in g/2 × 10 7 cells/ml). Mice (six per group) were sacrificed on day 12 post transplantation. Results (mean Ϯ s.d.) were statistically analysed using ANOVA with Scheffe posthoc test at P Ͻ 0.05 probability level. Numbers of white blood cells (WBC), lymphocytes and platelets are given as ×10 9 /l, and spleen colony-forming units (CFU-S) per spleen. There were no significant differences. e All groups differed significantly from group 1. Other group differences: 2 vs 4, 5 and 7; 3 vs 5, 6 and 7; 4 vs 2, 5, 6 and 7. Pharmacological pre-treatment consisted of 1 h incubation at 37°C. Drug concentrations are given in g/2 × 10 7 cells/ml. Cells were stimulated with 5 g con A and analysed after 3 days. number). The recovery of syngeneic marrow appeared better than that of allogeneic bone marrow chimeras, and in both the pre-treatment appeared to enhance the recovery. However, this difference was statistically significant for syngeneic chimeras only. In addition, a cytologic examination of BM smears taken on day 12 post transplantation revealed the presence of three haematopoietic lineages (granulocytic, erythroid and megakaryocytic) indicating successful engraftment in all groups except radiation controls (data not shown).
Pre-treatment of BM cells with HC and/or CsA affects T cell activation and differentiation
The findings of the pharmacologically mediated alleviation of GVHR in the allogeneic donor-host genetic combination prompted us to investigate the mechanisms of this phenomenon with regard to T cell surface antigen expression and cell cycle.
Inasmuch as mouse BM contains few T lymphocytes, these experiments were done with LNC, which contain some 80% of T cells. LNC (2 × 10 7 /ml) from C57BL/6J mice were pre-treated with 100 g/ml HC and/or 10 g/ml CsA, cultivated with con A and analysed by FC.
As expected, on day 3 of culture there was a considerable proliferation of mitogen-stimulated LNC cultures seen as an abundant blast-size cell population, which was absent in the cultures of cells pretreated with the drugs (data not shown).
CD4 and CD8 antigen expression of LNC was analysed after 1, 2 and 3 days of culture; data for day 3 from a representative experiment are shown in Table 4 . Mitogendriven proliferation of non-treated cells increased the proportions of CD4 − CD8 + and CD4 + CD8 + cells and simultaneously diminished the proportion of CD4 + CD8 − and CD4
− CD8 − cells. The pre-treatment with CsA strongly inhibited this avenue of differentiation, whereas HC was ineffective.
Cell cycle analysis on day 3 of culture showed an increase of the DNA content in mitogen-stimulated nonpre-treated cells. The pre-treatment of cells with the combination of HC and CsA abrogated this effect (data not shown).
A quantitative analysis of a representative experiment on /ml) pre-treated with 100 or 1000 g/ml HC and/or 10 or 100 g/ml CsA, cultured for 32 h with con A, followed by RNA extraction and RT-PCR procedure. The ␤-actin served as control (house-keeping gene) and was successfully amplified in all samples (Figure 4) . Both drugs applied alone or in combination suppressed the gene expression of IL-1 and IL-2; the effect of CsA appeared stronger, especially for IL-2 (Fig. 4) . Lower pre-treatment doses of the drugs stimulated the gene expression of GM-CSF while higher doses inhibited the gene expression of TGF-␤ (Figure 4 ).
Discussion
The key finding of this study is that a simple 1 h pre-treatment of BM cells with HC and CsA significantly alleviated GVHR in an allogeneic mouse donor-host genetic combination (Figures 2 and 3) , at the same time sparing in vitro BM cells' clonogenic (Table 2 ) and in vivo haematopoietic recovery (Table 3) potentials. In vivo mitigation of GVHR corresponded to the in vitro reduction of MLR (Table 1) . In clinical practice, the removal of transplant T lymphocytes is very important as a means to mitigate dangerous transplantation disease, 1, 6, 20 but it is also burdened with delayed recipient haematopoietic recovery, 4 increased frequency of infections 2 and graft rejection. 9 The purging technology in this study is simple and inexpensive, and spares not only transplant stem cells but also its T cells and their possible enhancement of the recipient's haematopoietic recovery, 21, 22 and avoids in vivo toxicity of the drugs.
11,14
The shapes of survival curves of recipients of allogeneic BM cells (Figures 2 and 3) suggest that HC and CsA pretreatment inhibited acute GVHR, whereas the effect on chronic GVHR was either minimal or absent. This is in accord with the fact that acute GVHR is caused by mature T cells in the transplant, 23, 24 whereas chronic GVHR is contained in delayed haematopoietic recovery due to inadequate T cell maturation in the irradiated thymus which distorts the CD4/CD8 cell ratio and precipitates autoantibody production and autoimmune pathology. 25 Inasmuch as the applied pre-treatment did not remove donor T cells from the transplant, its statistically significant mitigation of acute GVHR implies that the transplant T cells were functionally altered so as to lose their GVHR-inducing potential as seen through changes in CD4 and CD8 antigen expression (Table 4 ) and cytokine gene expression (Figure 4) . It is possible that the delayed deaths of allogeneic bone marrow recipients seen in the survival curves around day 50-60 ( Figures 2 and 3 ) might be due to delayed 'escape' of transplant T cells from functional alterations caused by the pretreatment, possibly through their differentiation into T H 2 cell type and subsequent production of alloantibodies which mediated chronic GVHR. 25 Our data on the pre-treatment's alteration of cytokine gene expression (Figure 4 ) are consistent with the notion that the pre-treatment preferably suppressed the T H 1 response. This has been also suggested by other authors. 13, 26, 27 The pre-treatment's effect on the BM cytokine network (Figure 4) indicates that it may mitigate GVHR potential through inhibition of gene expression of IL-1 and IL-2 (both doses), whereas through stimulation of GM-CSF (lower dose) and inhibition of TGF-␤ (higher dose) it may increase the beneficial influence on transplant engraftment. Generally speaking, the pre-treatment inhibited type 1 cytokine gene expression 12, 26 involved in GVHR-mediated tissue damage and GVHR mortality, 28 and increased gene expression of the haematopoietic growth factor GM-CSF 29 and reduced gene expression of the immunosuppressive and apoptotic cytokine TGF-␤. 27, 30 This notion is also in accord with the observed in vitro inhibition of MLR (Table 1) and con A-driven proliferation of bone marrow (Figure 1) , and lymph node activated CD4 + CD8 + and CD8 + T cells (Table 4) which are key GVHR effectors. 25, 31, 32 We believe that these effects significantly increased the survival of recipients of pre-treated allogeneic bone marrow (Figures 2  and 3) .
While CsA inhibited the differentiation of effector T cells, T cell activation, T cell growth factor (IL-2) secretion and cell cycle progression, and stimulated BFU-E formation, HC mainly reduced MLR, inhibited inflammatory cytokine secretion (IL-1) and stimulated GM-CSF secretion. Possible differences in inhibitory pathways may lead to the drugs additive effects (at lower doses). 33 CsAmediated inhibition of IL-2 secretion which in turn rescues T cells from apoptosis initiated by HC, 34 and/or drugs intracellular receptor interactions 35 may be the mechanisms responsible for their additive effects observed in our experimental model.
Although CsA and HC have been widely applied in clinical practice for post-transplantation prevention and suppression of GVHR, they have not been used for transplant pre-treatment and modification of post-transplantation effects of T cells. In this respect, our study offers a novel and potentially fruitful avenue of research aiming at the improvement of clinical bone marrow transplantation. Further research will certainly be needed to clarify the most effective HC and CsA dose combination to achieve maximal effects on GVHR inhibition, and to elucidate all mechanisms of their actions. The latter especially concerns differentiation of the pre-treatment effects on GVHR mitigation, GVHR inhibition of the haematopoietic recovery, and enhancement of the recovery by transplant spared T cells.
